Post-COVID-19 Organ Dysfunction: Mechanisms of Microvascular Damage and Therapeutic Strategies

Post-COVID-19 Organ Dysfunction: Mechanisms of Microvascular Damage and Therapeutic Strategies | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Post-COVID-19 Organ Dysfunction: Mechanisms of Microvascular Damage and Therapeutic Strategies Madiha Azeem This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7945283/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Microvascular dysfunction has proven to be the central mechanism of acute infection with Post-COVID-19 in the context of long-term multi-organ complications. The review aimed to evaluate the mechanisms, clinical manifestations and treatment considerations of microvascular injury in post-COVID and COVID-19. The wide search of the literature was conducted in databases of PubMed, Scopus, and Web of Science and referred to the studies published in the interval between 2019 and 2025. The results indicate that SARS-CoV-2 causes endothelial dysfunction, oxidative stress, microthrombi formation, disrupted tissue perfusion, and inflammatory tissue damage in organs. The ongoing endothelial damage also leads to cardiovascular, renal, pulmonary, and neurocognitive adverse events of long COVID. There is also evidence that microvascular vulnerability is aggravated by pre-existing comorbid conditions including diabetes, hypertension and dyslipidemia. The therapeutic plans focus on the significance of endothelial protection by the means of blood pressure level and glucose, lipid regulation, and anti-inflammatory measures. Critical Care & Emergency Medicine Microvascular dysfunction Endothelial injury Therapeutic strategies COVID-19 Post-COVID-19 Organ dysfunction Figures Figure 1 1.0 Introduction Microvascular damage or small vessel disease (SVD) is a pathophysiological mechanism of lesion from the microvasculature that are composed of small arterioles, capillaries and vessels [ 1 ]. This microvasculature helps the microcirculation of the systemic homeostasis and the organ specific homeostasis. Any rupture of the microvasculature can therefore have devastating effects on the organ functions. Injury causes the violation of blood circulation via the capillaries, insufficient exchange of nutrients and hypoxia within the tissues, consequently causing a cascade of pathological processes that ultimately lead to dysfunction of organs [ 2 ]. According to Koutsiaris and Karakousis (2025), microvascular damage does not normally manifest itself immediately. However, a progressive process may remain unnoticed clinically over the years until it causes observable symptoms [ 3 ]. The changes that typically occur in the early stages considered as minor including increased vascular rigidity, endothelial dysfunction, and reduced capillary density. Risk factors such as cholesterol elevation, systemic hypertension, or glucose intolerance could be the first manifestation of these changes [ 4 ]. However, these seemingly non-harmful conditions cause aggressive vascular damage and eventually, the emergence of chronic illnesses. Organs that are most prone to microvascular impairment are the heart, kidney, brain, liver and eyes since these organs require a much regulated blood capillary flow. Microvascular damage has long been associated with chronic conditions such as coronary artery disease, chronic renal disease, cerebrovascular diseases and diabetic retinopathy [ 5 ]. The microvascular damage has a complicated pathogenesis. One of the major factors and entails a syndrome that involves endothelium being unable to regulate vascular tone, thrombosis and inflammatory responses [ 6 ]. A wide range of factors including chronic inflammation, oxidative stress, dyslipidemia, and hyperglycemia can cause endothelial dysfunction. In particular, inflammation plays a significant role since it triggers the activities of leukocytes, platelets, increases vascular permeability, and prothrombotic states. Chronic stress has significant connection with microvascular changes including; over activity of sympathetic nervous system, hormonal imbalances and oxidative stress [ 7 ]. Additionally, microvascular damage might be acute during sepsis, ischemia-reperfusion damage, as well as a virus infection due to these long-term factors. Aging is also another determinant of microvascular impairment [ 8 ]. Blood vessels are become less elastic but it depends on the individual’s age, however, bi-sulfonic oxide bioavailability decreases and low grade inflammation becomes chronic [ 9 ]. The condition has become worsened by the presence of chronic disease ailments such as diabetes mellitus, blood pressure, and atherosclerosis diseases that are susceptible to microvascular malfunction and organ failures [ 10 ]. The contribution of microvascular damages to the dysfunction of organs was already an established phenomenon in different spheres of medicine before the COVID-19 pandemic appeared [ 11 ]. It was determined that coronary microvascular dysfunction on the cardiovascular system was a significant mediator in myocardial ischemia, as well as Hearts Failure with preserved Ejection Fraction (HFpEF) [ 12 ]. This is a frequent occurrence in patients with hypertension, diabetes, and obesity and indicates that even in the presence of considerable morbidity related to obstructive disease of the large-vessel coronary artery, therefore, the dysfunction of small vessels is still possible [ 13 ]. Microcirculation is central to the functioning of kidneys, which are very sensitive organ systems. In the study of Steegh et al. (2024), Chronic Kidney Disease (CKD) is characterized by glomerular endothelial damage and the subsequent capillary rarefaction [ 14 ]. These micro-vascular alterations reduce the nephron survival that leads to eventual establishment of progressive renal damage [ 15 ]. A significant cause of ischemic stroke, vascular loss of cognitive and dementia in the central nervous system is cerebral small vessel disease. Neuroimaging studies have reported that, the neurodegenerative processes in long-term are initially manifested by micro vascular changes which include white matter hyper intensity and lacunar infarcts [ 16 ]. Similarly, evidence of overall systemic vascularity demonstrated using the retina, the microvascular bed of which is readily visible. In combine, pre-pandemic Covid-19 results showed that the microvasculature plays a leading role in organ dysfunction development and evolution [ 17 ]. The pandemic of the new coronavirus SARS-CoV-2, called COVID-19, introduced evidence that was not previously revealed the importance of the microvascular state in the systemic state. Initially, the focus of researchers was on COVID-19 as a respiratory disease, subsequent clinical and pathological results revealed that the disease is a multi-organ pathology with vascular pathology playing the dominant role [ 18 ]. The SARS-CoV-2 infects the host cells via angiotensin-converting enzyme 2 (ACE2) receptors that are ubiquitously expressed in endothelial cells across several organ systems [ 19 ]. The long-term effects of COVID-19 include immune deregulation due to hyperactive inflammation, cytokine release and complement activation along with the direct infection by the virus [ 20 ]. Immune deregulation also affects the mechanisms of weakening the vascular integrity through the promotion of leukocyte adhesion, endothelial apoptosis, and widespread microthrombosis. The mechanisms were linked to clinical presentation of acute respiratory disease syndrome (ARDS), myocarditis, acute kidney disease, coagulopathy, nervous system issues (encephalopathy and cerebrovascular accident) [ 21 ]. It is worth noting that the overall results of autopsy analysis revealed that microthrombi and capillary congestion were prevalent in the lungs and even in heart, kidney, liver, and brain. Therefore, a systemic involvement is beneficial in the idea that COVID-19 is an endothelial disease where microvascular damage is the universal factor in connecting infection to multi-organ dysfunction [ 5 ]. Among the critical effects that observed to contribute to post-COVID-19 microvascular pathology are staggering of capillaries, endothelial regeneration loss, and microthrombi preservation [ 6 ]. Continuous low-grade inflammation may also lead to further vascular damage, meaning that microcirculatory functioning could be damage. The cause of such changes in the vascular system is the primary cause of the vast range of post-COVID-19 signs and symptoms such as chronic fatigue and exertional dyspnea and cognitive impairment [ 22 ]. 2.0 Literature Review 2.1 Overview of Microvascular Damages The terminology of Microvascular damage describes a structural and functional arteriolopathy of tissue rupture and exchange in terms of structural and functional changes of arterioles, capillaries and venules [ 9 ]. SVD identified as a significant contributor to organ dysfunction even before COVID-19. Coronary microvascular dysfunction shown to cause ischemia and heart failure with preserved ejection fraction. Similarly, glomerular endothelial injury and capillary rarefaction underlie chronic kidney disease, while cerebral small vessel pathology forms the basis of white matter disease, lacunar strokes, and vascular cognitive impairment [ 23 ]. Based on its pathophysiology, SVD attributed to endothelial mal-adaptation - loss of vasodilation through the mediation of nitric oxide, platelet and leucocyte adhesion, endothelial prothrombotic switch of chronic inflammation, oxidative stress, dyslipidemia and metabolic changes [ 24 ]. The consequence of alterations is increased obliteration of oxygen delivery and encourages tissue hypoxia and fibrosis, rarefaction of capillaries, augmented vascular rigidity and autoregulation failure. The initial microvascular dysfunctions most often remain nonclinical, and detected using functional imaging and testing (e.g. coronary flow reserve, retinal microvascular imaging, and state-of-the-art MRI scan of white-matter changes) [ 16 ]. 2.2 Mechanisms of Microvascular Damage The study of Sharma and Singh (2020) reviewed that a pathophysiological process of interdependent microvascular damage, endothelium activation/dysfunction, immune-mediated inflammation, and coagulation cascade abnormality, pericytes and structural remodeling loss [ 7 ]. Inflammatory mediators induce adhesion molecule (ICAM-1, VCAM-1) release by endothelial cells, stimulated leucocyte and endothelial migration reduces oxidative stress cell/avidity interaction of endothelial cells; inhibits vasodilation, promotes vasoconstriction [ 12 ]. It can lead to both the apoptosis and barriers disruption in both sepsis and viral cases, which come about because of direct viral infection or exposure to the proteins of the virus. SARS-CoV-2 in vascular cells- ACE2 and blocks renin-angiotensin system, however, selectively stimulates vasoconstriction, inflammation, and thrombosis [ 25 ]. Whereas, there is no conclusive evidence exists regarding endothelial tropism and that its expression reduced in endothelium in comparison to certain parenchymal cells, activation and damage to endothelium never reported not to happen in COVID-19 [ 22 ]. The contribution of coagulopathy, endotheliopathy results in development of procoagulant endothelial surface, tissue factor expression, platelet-activation, and complement interaction to micro- clotting that blocks capillaries and increases ischemia. The additional destruction of the microvascular networks presupposes the dysfunction of the pericytes and the capillary erosion with its resultant chronic hypo-perfusion and remodeling fibrotic [ 15 ]. 2.3 Symptoms of Microvascular Damage in COVID-19 The multi-organ hypoperfusion, inflammation, and microthrombosis correlations are heterogeneous constellations of acute and persistent symptoms that are microvascular injuries due to the coronavirus disease. Pulmonary microangiopathy, severe hypoxemia and non-responding ARDS also involves capillary congestion, endothelial cell inflammation, endothelial thrombus and barricades the gaseous exchange [ 21 ]. Research studies conducted in the long-term follow up indicate that outcome of a heart failure patient under functional examination is myocarditis-like symptoms and heart failure-cardiac symptoms exercise intolerance [ 22 ]. A narrative review by Korompoki et al. (2021), the neurological phenomenon explained by small-vessel brain damage identified both in postmortem microvascular histopathology and MRI (microinfarcts, white-matter hyperintensities) is an association with both acute and post-acute COVID-19 - headache, encephalopathy, cognitive impairment (brain fog) and focal neurologic impairment [ 12 ]. Microvascular impairment, absence of endothelial repair/low grade inflammation, resulting in systemic functioning, systemic symptoms of progressively weak condition, post-exertional fatigue and orthostatic intolerance (dysautonomia) and exertional malaise is present [ 26 ]. These abnormalities of endothelium and consequently role of vascular system in the syndromes have proven over many months of infection following clinical cohort studies and vascular functional studies [ 23 ]. 2.4 Microvascular Complications and Predictors The high susceptibility to the thrombotic complications are linked with the degeneration of the organ system and the abundance of the pathological correlate of microvascular thrombosis is also linked with the occurrence of thrombotic foci in the lungs, pulmonary microthrombi and venous thromboembolism [ 5 ]. Also along with poor results in microthrombi and endothelium harm are also similar outcomes that appeared across lungs and body in the case of autopsy studies [ 14 ]. Predictive disease outcomes depends on age are cardiovascular disease, diabetes mellitus, overweight, the existence of systemic inflammation and coagulopathy (high D-dimer, CRP, ferritin). The severity of the disease and death is also associated with heightened symptoms of the mobilization of the endothelium cells (vWF antigen, thrombomodulin) [ 16 ]. The criterion of assessment of anticoagulation approaches during the onset of the pandemic to prevent the risk of thrombosis was randomized and observational studies. The causality of coagulopathy in complications of non-critical population established, however, the causality of coagulopathy as the mediator of the bleeding risk and bleeding tendency of timely selection [ 4 ]. 2.5 Risk Factors due to Microvascular Damage Risk factors of microvascular damage only revealed in the classic cardiometabolic risk, however, also increased the chances of other organs damage [ 27 ]. It might result in capillary rarefaction and dysautoregulation as a sequela of development of preexisting endothelial dysfunction by chronic low-grade inflammation, oxidative stress, glycation, lipid peroxidation and hyperglycemia, lipidemia, obesity and smoking [ 7 ]. These risk factors also precondition the most disagreeable results of COVID-19 and worse microvascular injuries during its infection [ 28 ]. Age is also a risk factor that can cause vascular stiffness, the unavailability of bioavailability of nitric oxide and inflammation elevate the microvascular decompensation threshold. SARS-CoV-2 virus could intervene to provoke angina pro avia organ dysfunction in the patient with innate stress of microvascular disease (diabetic retinopathy, glomerular endothelial damage by CKD) [ 13 ]. Genetic predilection, sexual problems, socioeconomic factors (access to care, burden of comorbidities) moderate risk and outcomes. Among the biomarkers used to identify COVID-19 patients with weakened endothelium with outsize microvascular damage are increased baseline vWF, factor Eight and pro-inflammatory cytokine [ 11 ]. The measures like minimization of the danger in glycemic regulation, blood pressure regardless of the drugs, lipids reduction, smoking toleration are continuing to assume the leading part on the stage of the prevention of the chronic SVD and exposure to the danger of the definite injury vascular [ 21 ]. 2.6 Effect of Covid-19 on other Organ Dysfunction These are outcomes of microvascular brain destruction on imaging and inflammatory and coagulopathy, linked to post-COVID syndromes of the nervous system, which are manifested as cognitive disability, headaches and dysautonomia. The enduring microclots, incompleteness and capillary rarefaction of endothelium, have been proposed to be the eternal suffer-making processes [ 29 ]. Renal diseases present with a wide range of signs and symptoms, with most patients who survived acute kidney injuries recovering in the meantime, however, presenting a gradual malfunction, because of irreversible microvascular and interstitial damages. The risk of SVD may also increase when reported during the long-term, fresh or worsening cardiometabolic decrease (new or worsening diabetes, high blood pressure) at the post-COVID-19 stage [ 30 ]. 2.7 Organ Dysfunction Post Covid-19 In the cohort study for epidemiology, higher risk of non-remitting organ dysfunction is predicted by severity of the acute illness, old age, comorbidities, and indicators of coagulopathy/inflammation [ 26 ]. In patients with mild acute disease, long-term symptoms have reported, and it is even possible that microvascular damage and general immune maladaptation has experienced at both ends of the severity spectrum. Longitudinal research has continued to delimit directions and to determine reversible and progressive injury of microvascular mediation of organs. Functions of various organs are dysfunctional stunning microvascular damage with SARS-CoV-2. The absence of ventilation-perfusion correspondence and microangiopathy of the lungs are among the origins of severe hypoxemia and prolonged respiratory failure [ 29 ]. Kidney involvement is often a sign of a superimposition of acute tubular injury on the malfunctioning of the glomerular endothelium, endothelial swelling and microthrombi were found in kidney autopsy and heightened poorer outcome and augmented advance of chronic kidney illnesses in patients with acute kidney injury in hospital [ 23 ]. In results, of microvascular inflammation and microthrombi, microinfarcts, hemorrhagic lesions and visualization of blood-brain barrier damage has linked with neurological conditions developing clinically as encephalopathy, stroke and cognitive impairment. Retina gives us a window into the health of the microvessels in the system and it has noticed that the retinal mirrors have changed following the covid and these are symptoms of the damage to the vascular system [ 25 , 31 ]. Microvascular congestion and ischemia related to liver and gastrointestinal symptoms and the endothelium dysfunction stimulates a prothrombotic condition, which, in turn, may result in the formation of multi-organ failure. The vascular footprint of COVID-19 is an explanatory characteristic of heterogeneous organ intrusions at acute and post-acute phases [ 32 ]. 2.8 Effective Interventions used for Organ Dysfunctions Therapeutic interventions to control COVID-19 associated microvascular damage include anticoagulation, anti-inflammation, endothelial protective, and rehabilitation practices [ 17 ]. Preliminary clinical studies with anticoagulation showed that therapeutic anticoagulation of heparin decreased thrombotic complications in hospitalized environment. According to Lucijanic et al. (2023), for patients in non-critical conditions emphasized that timely antithrombotic therapy is essential to balance thrombotic risk [ 33 ]. Anti-inflammatory foods (e.g., corticosteroids, IL-6 inhibitors) inhibit high-incidence inflammatory endothelial activation in acute COVID-19, decreasing progression to respiratory failure and presumed to be able to mitigate downstream microvascular damage. Statins and ACE inhibitors/ARBs postulated to have endothelial protective effects through pleiotropic anti-inflammatory and vasculo protective effects [ 34 ]. Functional correction resulting in microvascular impairment addressed by rehabilitative and supportive intervention (graded exercise, autonomic retraining, oxygen, cardiopulmonary rehabilitation). The possibilities of new regenerative strategies such as endothelial progenitor cell therapy and angiogenic or endothelial repair agents are under preclinical/early clinical trial as potential methods of repairing microcirculatory integrity. Vascular biomarker and retinal imaging and functional microcirculatory testing monitoring can inform personalized treatment and help phenotype patients, possibly to benefit more with vascular protective therapy intensification [ 6 ]. 3.0 Methodology 3.1 Research Design The review employed integrative review design to determine, appraise and integrate published data on the relationship between COVID-19, microvascular injury and multi-organ dysfunction. The integrative review approach based on five steps model proposed by Whittemore and Knafl (2005) has employed (See Fig. 1): (1) problem identification, (2) literature search, (3) data evaluation, (4) data analysis, and (5) presentation. This methodology was chosen because it incorporates different study designs to obtain a panoramic view of a complex, multi-system condition following COVID-19 induced microvascular damage. 3.2 Search Strategy Different electronic databases, including PubMed, Scopus, Web of Science, EMBASE, CINAHL, PsycINFO, Cochrane Library, and Google Scholar used to gather information on published articles in peer-reviewed journals. The literature search has designed to constrain the search to articles published no earlier than 2019, and not later than 2025 to review the most recent output with regards to COVID-19. Searching done by using Medical Subject Headings (MeSH) along with the free-text key word to reach as many articles as possible. The keywords included: COVID-19, SARS-CoV-2, microvascular damage, small vessel disease, endothelial dysfunction, organ dysfunction, multiorgan failure, post-COVID syndrome, long COVID, post-acute sequelae of SARS-CoV-2 (PASC), microthrombosis, inflammation and endotheliitis. To enhance searching and avoid irrelevant results, these words were searched using Boolean operators such as AND, OR and NOT. Examples of such search terms might include COVID-19 AND microvascular damage AND organ dysfunction or SARS-CoV-2 AND endothelial dysfunction OR microthrombosis. Table 1 presented databases and keywords for study selection. 3.3 Search Strings Search strings were developed to support the comprehensive and systematic literature search through the integration of a combination of keywords and Boolean operators (AND, OR, and NOT). Below, the unique combinations of keywords provided to each database, to optimize the retrieval of relevant articles and minimize irrelevant results. "COVID-19 AND Microvascular Damage AND Organ Dysfunction AND Endothelial Injury" "SARS-CoV-2 AND Small Vessel Disease OR Capillary Dysfunction AND Inflammation" "Post-COVID Syndrome AND Microvascular Complications AND Multiorgan Dysfunction AND Hypoxia" "COVID-19 AND Endothelial Dysfunction AND Microthrombosis OR Organ Impairment AND Risk Factors" 3.4 Eligibility Criteria It is important to apply eligibility criteria during the selection process to check the credibility of sources used in review article. Studies published after 2019 were included from peer-reviewed journals and written in English language considered as eligible. Selected studies included the association between COVID-19 and microvascular damage, small vessel disease, or organ dysfunction. Both review articles and clinical research studies that included human subjects were included regardless of research design. Table 2 showed the inclusion and exclusion criteria for this study. 3.5 Selection of Studies A preliminary search of the database located 1,280 studies. This removed 1,045 titles and abstracts. Of these, 184 articles reviewed in their entirety. Around 42 articles have selected for the final analysis and findings after applying inclusion and exclusion criteria. After final selection, some other relevant research studies that were included through a snowballing technique to determine the final 45 studies dataset. 3.6 Data Quality Assessment Tool Two reviewers evaluated the selected studies independently against the methodological consistency, relevance, and microvascular pathology focus in COVID-19. Quality tools were used (CASP checklist (qualitative and observational studies) and Cochrane risk-of-bias tool (trials). The tool assists the reviewers to establish the credibility of the study findings and the evidence strength in general [ 35 ]. 3.7 Data Extraction A structured extraction form used to document data on authors, year, study design, setting, sample size, population, methodological approach, key findings, and reported microvascular / organ outcomes. Mechanisms of microvascular damage, organ specific effects, risk factors, predictors of dysfunction, and treatment methods ascertained using the thematically extracted data. Synthesized themes chosen to provide a composite perspective of the pathophysiology of microvascular injury in post-COVID organ dysfunction. 4.0 Results Among 45 selected studies for this review article, 20 sources chosen for analysis. The studies carried out in different geographical settings such as the United States, Europe, Asia, and the Middle East and their designs were narrative reviews, cross-sectional analyses, mechanistic, and clinical cohort studies. Most of the studies cited for endothelial damage, microthrombosis, and microvascular inflammation to present the connection between an infection with SARS-CoV-2 and multi-organ injury. Moreover, existing research noted complications in cardiovascular, renal, pulmonary, and neurological systems in addition to persistent endothelial dysfunction in long COVID-19 [ 36 ]. Some investigated therapeutic approaches, including blood pressure and glucose control. Also, new targets such as microclot dissolution, mitochondrial protection and autonomic modulation. See Table 3 for the summary of selected studies with key findings. In the table 3, a summary of 20 studies provided that were included or considered for the analysis and discussion section of the review article. [Insert Table 3] 5.0 Discussion 5.1 Microvascular Injury in Acute COVID-19 The acute infection with SARS-CoV-2 has a deep impact on the vascular system, and microvascular damage becomes one of the primary causes of dysfunction of acute organs. The endothelial cells infected through ACE2 receptors, which triggers endothelial inflammation, apoptosis, and general endothelialitis [ 19 ]. This disruption of the endothelium leads to impairment of vascular homeostasis, loss of barrier integrity, increased vascular permeability, and the initiation of thrombo inflammatory cascades [ 23 ]. Oxidative stress, nitric oxide imbalance, and a pro-thrombotic condition are some of the unifying features of this phase [ 37 ]. This leads to capillary rarefaction and poor perfusion that worsens oxygenation, particularly in tissues with high oxygen demands, like the brain, heart, and lungs [ 14 ]. It also leads to the creation of a pro-inflammatory environment, which enhances the release of cytokines and the formation of microclots, which further worsen vascular pathology [ 38 ]. 5.2 Vascular Sequelae of Post COVID-19. Persistent vascular complications in survivors of COVID-19 are long-term and collectively referred to as post-COVID vascular sequelae. Such sequuelae are the result of viral persistence, immune dysregulation and unresolved endothelial damage, producing a chronic endotheliopathy state [ 8 ]. Attacked endothelial cells do not entirely recover their regulatory properties, causing long-lasting vascular inflammation, microclot retention, and broken repair processes [ 3 ]. The microvascular alterations such as fibrosis, remodeling of the extracellular matrix and rarefaction of vessels are the main targets of long-term research of vascular pathology [ 13 , 14 ]. The example of vascular fibrosis in the myocardium and pulmonary circulation, which is correlated with the reduction of the vascular compliance, absence of the perfusion, and increased risk of chronic heart and lung diseases [ 10 ]. Cognitive impairment and fatigue are the main symptoms of post-COVID-19 which are gradually correlated with neurologically persistent microvascular dysfunction and capillary rarefaction in cerebral vessels [ 39 ]. These results are accompanied by the ones indicating the existence of chronic cerebrovascular inflammation and dysfunction of neurovascular coupling as predisposing factors to the patients with vascular cognitive impairment and mood disturbances [ 40 ]. The renal sequelae have been reported in which the endothelial damage of the glomerulus speeds up chronic kidney disease and irreversible renal dysfunction [ 14 ]. Notably, such sequelae go beyond morphological alterations to morphological functions of the vascular regulating systems. Oxidative stress persistence, a disproportion of nitric oxide and dysfunctional mitochondriums maintain an endothelial vulnerability environment [ 20 , 4 ]. This pathophysiology triggers chronic risks of hypertension, thrombosis, and cardiovascular events in the context of which there is a concern about the accelerated vascular aging of post-COVID populations [ 32 ]. 5.3 Multiple Organ Dysfunctions – Evidence-Based Findings COVID-19 has become a systemic disease whose microvasculars are extensively involved, which causes the dysfunction of many organs. There is a number of evidences that SARS-CoV-2 causes endothelial injury and capillary microthrombosis that worsen tissue perfusion and are associated with organ-specific pathologies outside the respiratory system [23). The cause of this multi-organ effect is that the viral entry occurs via angiotensin-converting enzyme 2 (ACE2) receptors that are highly expressed in the heart, kidneys, lungs, liver, and brain causing both direct viral cytotoxicity and indirect immune-mediated damage. The cardiac organ dysfunction during the Post-Covid-19 entails coronary microvascular dysfunction, and endothelial inflammation [ 12 ]. Another study by Riou et al. (2024) revealed that pulmonary microvascular injury is a key cause of organ dysfunction due to endothelial cell apoptosis, fibrin deposition, and vascular remodeling that had an effect on oxygen exchange. Long-lasting pulmonary hypertension and fibrotic remodeling have been reported in post-COVID patients, which is evidence of long-term damage of alveolar capillary networks [ 41 ]. This pulmonary vasculopathy is believed to be one of the major causes of long COVID chronic dyspnea and exercise intolerance. Moreover, cerebral microvascular injury such as impairment of blood brain barrier, neuroinflammation, and microthrombi are also becoming more apparent due to some dysfunction of some of the neurological organs. 5.4 Therapeutic Strategies Treatment of post-COVID organ dysfunction should be based on the complex of intervention of the vascular endothelium, inflammation, and metabolism. Because endothelial damage is at the center of the COVID-19 pathology, the restoration of vascular integrity and the prevention of additional malfunction became the priorities of clinical care [ 37 ]. It has been indicated in recent evidence that traditional cardiovascular, metabolic, and anti-inflammatory interventions are capable of reducing microvascular complications and enhancing long-term recovery. Blood pressure, glycemic and lipid metabolism optimization is an important factor in the minimization of endothelial stress and the enhancement of microcirculatory flow. 5.4.1 Blood Pressure Control Proper blood pressure management is essential in the maintenance of endothelial activity and minimization of microvascular injury after COVID. Research has found that uncontrolled hypertension increases the severity of vascular stiffness and oxidative stress to aggravate endothelial dysfunction in post-recovery patients [ 42 ]. Protective effects have been proven by the use of ACE inhibitors and angiotensin receptor blockers (ARBs) that enhance the bioavailability of nitric oxide and endothelial homeostasis [ 43 ]. Beta-blockers and calcium channel blockers can also help to eliminate postural tachycardia and autonomic imbalance that are commonly reported in long COVID [ 44 ]. 5.4.2 Diabetes Management Oxidative stress of endothelium and inflammation by increased role of post-COVID hyperglycemia and insulin resistance. As can be seen, a strict glycemic control can enhance the vascular reactivity and decrease thrombotic complications [ 7 ]. SGLT2 inhibitors, metformin and GLP-1 receptor agonists have been discovered to exhibit endothelial-protective effects and SGLT2 inhibitors to have lower post-COVID-19 diabetic inflammatory biomarker [ 27 ]. 5.4.3 Cholesterol Control One of the risk factors of vascular inflammation is dyslipidemia, which is viewed as modifiable among long COVID patients. The pleiotropic anti-inflammatory and antioxidant effects of statins are highly recommended to address the injury of endothelial cells and enhance the production of nitric oxide [ 15 ]. Various observational studies have recommended statin therapy to have a positive effect on vascular compliance and a reduced post-COVID cardiovascular complication rate [ 45 ]. In addition to statins, PCSK9 inhibitors and omega-3 fatty acids have also been suggested due to their possible advantages in reducing the vascular fibrosis and systemic inflammation [ 18 ]. 5.4.4 Management of Hypertension RAAS imbalance, endothelial stiffness, and persistent inflammation could be the causes of persistent hypertension after COVID-19 [ 36 , 4 ]. RAAS modulators, nitric oxide donors, and antioxidant therapy have been shown to be promising therapeutic methods in terms of decreasing vascular resistance [ 1 , 2 ]. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists have been used in combination with one another to reverse endothelial dysfunction and reduce inflammatory mediators. In addition, lifestyle changes including salt, aerobic, and stress reduction also improve vascular recovery [ 22 ]. See Table 4 below, an evidence-based therapeutic strategies for post-COVID-19 microvascular and organ dysfunction (2020–2025). 6.0 Conclusion In conclusion, the review about microvascular dysfunction is central to the relationship between SARS-CoV-2 infection and multiple organ dysfunction that is observed in both the acute and post-acute phases of COVID-19. The results indicate that COVID-19 is not a pulmonary disease, however, a vascular system disease, which is characterized by endothelium injury, inflammation, and distortions in coagulations. The processes have disrupted specific organ microcirculation and caused cardiac, renal, hepatic and neurological complications. This review indicates that people with pre-existing diseases like hypertension, diabetes, and dyslipidemia are more susceptible to severe microvascular damage and chronic problems. Continuous symptoms such as fatigue, impaired cognition, and dysfunction of the cardiovascular system only underline the chronicity of post-COVID-19 microvascular damage. 7.0 Limitations and Strengths The review used published literature sources between 2019 and 2025. A number of studies involved were limited to small data size, which restricted the ability to generalize the results to other populations. The study designs and diagnostic criteria of post COVID-19 contributed to variability and comparability of the findings. This review is limited to synopsis between the microvascular injury mechanisms and the multi-organ dysfunction and therapeutic implications. Declarations Disclosure Statement : The author declared that sources of information were cited appropriately in this review and no conflicts of interest or other financial funding exist that affected the content of this work. Acknowledgement : None Conflict of Interest : The author declares no conflict of interest Funding : This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. References Pelle MC, Zaffina I, Lucà S et al (2022) Endothelial dysfunction in COVID-19: potential mechanisms and possible therapeutic options. Life 12(10):1605 Ahamed J, Laurence J, Long (2022) COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Investig. ;132(15) Koutsiaris AG, Karakousis K, Long COVID, Mechanisms (2025) Microvascular Effects, and Evaluation Based on Incidence. Life 15(6):887 Halawa S, Aguib Y, Yacoub MH (2023) In search for molecular mechanisms of Post COVID-19 vascular damage. Cell Signal 1(1):85–89 Yin J, Wang S, Liu Y et al (2021) Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation 28(7):e12718 Crea F, Montone RA, Rinaldi R (2022) Pathophysiology of coronary microvascular dysfunction. Circ J 86(9):1319–1328 Sharma VK, Singh TG (2020) Chronic stress and diabetes mellitus: interwoven pathologies. Curr Diabetes Rev 16(6):546–556 Gupta G, Buonsenso D, Wood J et al (2025) Mechanistic Insights Into Long Covid: Viral Persistence, Immune Dysregulation, and Multi-Organ Dysfunction. Compr Physiol 15(3):e70019 Kei CY, Singh K, Dautov RF et al (2023) Coronary microvascular dysfunction: evolving understanding of pathophysiology, clinical implications, and potential therapeutics. Int J Mol Sci 24(14):11287 Goerlich E, Chung TH, Hong GH et al (2024) Cardiovascular effects of the post-COVID-19 condition. Nat Cardiovasc Res 3(2):118–129 Khan MN (2024) Post-COVID-19 Cardiac Complications: Understanding the Immune Niche Alterations in the Heart. Indian Practitioner. ;77(7) Wang Y, Zhang J, Wang Z et al (2023) Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction. Heart Fail Rev 28(1):169–178 Li J, Zhou Y, Ma J et al (2023) The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduct Target therapy 8(1):416 Steegh FM, Keijbeck AA, de Hoogt PA et al (2024) Capillary rarefaction: a missing link in renal and cardiovascular disease? Angiogenesis 27(1):23–35 Sideratou C-M, Papaneophytou C (2024) Persistent vascular complications in long COVID: The role of ACE2 deactivation, microclots, and uniform fibrosis. Infect Disease Rep 16(4):561–571 Rudilosso S, Rodríguez-Vázquez A, Urra X et al (2022) The potential impact of neuroimaging and translational research on the clinical management of lacunar stroke. Int J Mol Sci 23(3):1497 Matsuishi Y, Mathis BJ, Shimojo N et al (2021) Severe COVID-19 infection associated with endothelial dysfunction induces multiple organ dysfunction: a review of therapeutic interventions. Biomedicines 9(3):279 Kamdar A, Sykes R, Thomson CR et al (2024) Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions. Infect Med 3(4):100147 Ashraf UM, Abokor AA, Edwards JM et al (2021) SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genom 53(2):51–60 Georgieva E, Ananiev J, Yovchev Y et al (2023) COVID-19 complications: oxidative stress, inflammation, and mitochondrial and endothelial dysfunction. Int J Mol Sci 24(19):14876 Ramadori GP (2023) Organophosphorus poisoning: Acute respiratory distress syndrome (ARDS) and cardiac failure as cause of death in hospitalized patients. Int J Mol Sci 24(7):6658 Visco V, Vitale C, Rispoli A et al (2022) Post-COVID-19 syndrome: involvement and interactions between respiratory, cardiovascular and nervous systems. J Clin Med 11(3):524 Xu S-w, Ilyas I, Weng J-p (2023) Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin 44(4):695–709 Vlaming-van Eijk LE, Tang G, Bourgonje AR et al (2025) Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies. J Pathol Kruger A, Joffe D, Lloyd-Jones G et al (eds) (2024) Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers, Inc. Korompoki E, Gavriatopoulou M, Hicklen RS et al (2021) Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect 83(1):1–16 Peluso MJ, Deeks SG (2024) Mechanisms of long COVID and the path toward therapeutics. Cell 187(20):5500–5529 He St, Wu K, Cheng Z et al (2022) Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions. MedComm 3(4):e196 Maltezou HC, Pavli A, Tsakris A (2021) Post-COVID syndrome: an insight on its pathogenesis. Vaccines 9(5):497 Gomazkov O (2023) Post-Covid Syndrome: Pathophysiology of Systemic Dysregulations. Biology Bull Reviews 13(6):590–598 Wu X, Xiang M, Jing H et al (2024) Damage to endothelial barriers and its contribution to long COVID. Angiogenesis 27(1):5–22 Gyöngyösi M, Alcaide P, Asselbergs FW et al (2023) Long COVID and the cardiovascular system—elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovascular Res 119(2):336–356 Lucijanic M, Tjesic-Drinkovic I, Piskac Zivkovic N et al (2023) Incidence, risk factors and mortality associated with major bleeding events in hospitalized COVID-19 patients. Life 13(8):1699 Cimmino G, D’Elia S, Morello M et al (2025) Cardio-Pulmonary Features of Long COVID: From Molecular and Histopathological Characteristics to Clinical Implications. Int J Mol Sci 26(16):7668 Campbell KA, Cammer A, Moisey LL et al (2024) Critically appraising and utilising qualitative health research evidence in nutrition practice. J Hum Nutr Dietetics 37(1):377–387 Allendes FJ, Díaz HS, Ortiz FC et al (2023) Cardiovascular and autonomic dysfunction in long-COVID syndrome and the potential role of non-invasive therapeutic strategies on cardiovascular outcomes. Front Med 9:1095249 Ambrosino P, Calcaterra IL, Mosella M et al (2022) Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines 10(4):812 Charfeddine S, Ibn Hadj Amor H, Jdidi J et al (2021) Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med 8:745758 Fekete M, Lehoczki A, Szappanos Á et al (2025) Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. GeroScience. :1–35 Bhattacharjee N, Sarkar P, Sarkar T (2023) Beyond the acute illness: exploring long COVID and its impact on multiple organ systems. Physiol Int 110(4):291–310 Riou M, Coste F, Meyer A et al (2024) Mechanisms of pulmonary vasculopathy in acute and long-term COVID-19: a review. Int J Mol Sci 25(9):4941 Karakasis P, Nasoufidou A, Sagris M et al (2024) Vascular alterations following COVID-19 infection: A comprehensive literature review. Life 14(5):545 Batiha GE-S, Al-Kuraishy HM, Al-Gareeb AI et al (2022) Pathophysiology of post-COVID syndromes: a new perspective. Virol J 19(1):158 Fedorowski A, Fanciulli A, Raj SR et al (2024) Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden. Nat Reviews Cardiol 21(6):379–395 Becker RC (2020) Anticipating the long-term cardiovascular effects of COVID-19. J Thromb Thrombolysis 50(3):512–524 Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7945283","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":534773665,"identity":"99f33ec6-3a61-4fdb-8666-15c3c8db799a","order_by":0,"name":"Madiha Azeem","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0UlEQVRIiWNgGAWjYFAD9gYgYWBBihaeAyAtEqRokUgAk4QV8vcfPvjoZg5DYv/M51c3/CiQYOBv707Ab/aBY8nGudsYEmfczim72QN0mMSZsxvwW3Owx0waqCW34XZO2g0eoBYDiVz8WuQP83//DdIy/+aZtJt/iNFicIyHjRmkZcMN9mO3ibLF8AybMdBhEvUbz+Sw3ZYxkOAh6Be584cffs7dZmMsd/z4s5tv/tjI8bf3EvA+BICig8cAxOIhRjkMsD8gRfUoGAWjYBSMIAAAq3pIgES7cnkAAAAASUVORK5CYII=","orcid":"","institution":"Jinnah University for Women","correspondingAuthor":true,"prefix":"","firstName":"Madiha","middleName":"","lastName":"Azeem","suffix":""}],"badges":[],"createdAt":"2025-10-27 09:33:59","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-7945283/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7945283/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":94575994,"identity":"08908823-e2f4-434e-b671-69978ed023f0","added_by":"auto","created_at":"2025-10-28 18:09:44","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":69983,"visible":true,"origin":"","legend":"","description":"","filename":"ManuscriptwithoutAuthorDetail.docx","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/b8f8281b2a2b933866885bba.docx"},{"id":94577718,"identity":"f26f1f26-52b9-413e-9065-c8539a299aad","added_by":"auto","created_at":"2025-10-28 18:10:23","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":342,"visible":true,"origin":"","legend":"","description":"","filename":"rs7945283.json","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/6c0246609201977f59abb34f.json"},{"id":94577268,"identity":"25acaedf-4748-41ed-94e6-cd27dabe3ff6","added_by":"auto","created_at":"2025-10-28 18:10:18","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":94509,"visible":true,"origin":"","legend":"","description":"","filename":"rs79452830enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/321e0e7ea2a2f58d9d5d1a12.xml"},{"id":94576280,"identity":"a2a363cb-1432-4017-923b-1092c11e712a","added_by":"auto","created_at":"2025-10-28 18:09:57","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":93010,"visible":true,"origin":"","legend":"","description":"","filename":"rs79452830structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/25a2d76166a628cb924c9d0f.xml"},{"id":94576209,"identity":"b6c414f5-8ce6-4581-8982-a4a8d5bc08ac","added_by":"auto","created_at":"2025-10-28 18:09:57","extension":"html","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":100297,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/c1fb9c4135c05514cc4831a4.html"},{"id":94575977,"identity":"7e952ff7-def5-4b9d-b385-22196ea13b0a","added_by":"auto","created_at":"2025-10-28 18:09:44","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":50985,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cem\u003e\u003cstrong\u003eFive Steps Framework for Integrative Review (Source: Author)\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/468a2d032cc57fe509c0e003.jpg"},{"id":94594836,"identity":"683b5d83-42cb-48f6-8de2-d56d597757f8","added_by":"auto","created_at":"2025-10-28 18:30:42","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":832996,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7945283/v1/14cf5b62-125f-416f-a8d9-bfe767e15ad2.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003ePost-COVID-19 Organ Dysfunction: Mechanisms of Microvascular Damage and Therapeutic Strategies\u003c/p\u003e","fulltext":[{"header":"1.0 Introduction","content":"\u003cp\u003eMicrovascular damage or small vessel disease (SVD) is a pathophysiological mechanism of lesion from the microvasculature that are composed of small arterioles, capillaries and vessels [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. This microvasculature helps the microcirculation of the systemic homeostasis and the organ specific homeostasis. Any rupture of the microvasculature can therefore have devastating effects on the organ functions. Injury causes the violation of blood circulation via the capillaries, insufficient exchange of nutrients and hypoxia within the tissues, consequently causing a cascade of pathological processes that ultimately lead to dysfunction of organs [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAccording to Koutsiaris and Karakousis (2025), microvascular damage does not normally manifest itself immediately. However, a progressive process may remain unnoticed clinically over the years until it causes observable symptoms [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. The changes that typically occur in the early stages considered as minor including increased vascular rigidity, endothelial dysfunction, and reduced capillary density. Risk factors such as cholesterol elevation, systemic hypertension, or glucose intolerance could be the first manifestation of these changes [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. However, these seemingly non-harmful conditions cause aggressive vascular damage and eventually, the emergence of chronic illnesses. Organs that are most prone to microvascular impairment are the heart, kidney, brain, liver and eyes since these organs require a much regulated blood capillary flow. Microvascular damage has long been associated with chronic conditions such as coronary artery disease, chronic renal disease, cerebrovascular diseases and diabetic retinopathy [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe microvascular damage has a complicated pathogenesis. One of the major factors and entails a syndrome that involves endothelium being unable to regulate vascular tone, thrombosis and inflammatory responses [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. A wide range of factors including chronic inflammation, oxidative stress, dyslipidemia, and hyperglycemia can cause endothelial dysfunction. In particular, inflammation plays a significant role since it triggers the activities of leukocytes, platelets, increases vascular permeability, and prothrombotic states. Chronic stress has significant connection with microvascular changes including; over activity of sympathetic nervous system, hormonal imbalances and oxidative stress [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAdditionally, microvascular damage might be acute during sepsis, ischemia-reperfusion damage, as well as a virus infection due to these long-term factors. Aging is also another determinant of microvascular impairment [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Blood vessels are become less elastic but it depends on the individual\u0026rsquo;s age, however, bi-sulfonic oxide bioavailability decreases and low grade inflammation becomes chronic [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. The condition has become worsened by the presence of chronic disease ailments such as diabetes mellitus, blood pressure, and atherosclerosis diseases that are susceptible to microvascular malfunction and organ failures [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe contribution of microvascular damages to the dysfunction of organs was already an established phenomenon in different spheres of medicine before the COVID-19 pandemic appeared [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. It was determined that coronary microvascular dysfunction on the cardiovascular system was a significant mediator in myocardial ischemia, as well as Hearts Failure with preserved Ejection Fraction (HFpEF) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. This is a frequent occurrence in patients with hypertension, diabetes, and obesity and indicates that even in the presence of considerable morbidity related to obstructive disease of the large-vessel coronary artery, therefore, the dysfunction of small vessels is still possible [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eMicrocirculation is central to the functioning of kidneys, which are very sensitive organ systems. In the study of Steegh et al. (2024), Chronic Kidney Disease (CKD) is characterized by glomerular endothelial damage and the subsequent capillary rarefaction [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. These micro-vascular alterations reduce the nephron survival that leads to eventual establishment of progressive renal damage [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. A significant cause of ischemic stroke, vascular loss of cognitive and dementia in the central nervous system is cerebral small vessel disease. Neuroimaging studies have reported that, the neurodegenerative processes in long-term are initially manifested by micro vascular changes which include white matter hyper intensity and lacunar infarcts [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Similarly, evidence of overall systemic vascularity demonstrated using the retina, the microvascular bed of which is readily visible. In combine, pre-pandemic Covid-19 results showed that the microvasculature plays a leading role in organ dysfunction development and evolution [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe pandemic of the new coronavirus SARS-CoV-2, called COVID-19, introduced evidence that was not previously revealed the importance of the microvascular state in the systemic state. Initially, the focus of researchers was on COVID-19 as a respiratory disease, subsequent clinical and pathological results revealed that the disease is a multi-organ pathology with vascular pathology playing the dominant role [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. The SARS-CoV-2 infects the host cells via angiotensin-converting enzyme 2 (ACE2) receptors that are ubiquitously expressed in endothelial cells across several organ systems [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe long-term effects of COVID-19 include immune deregulation due to hyperactive inflammation, cytokine release and complement activation along with the direct infection by the virus [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Immune deregulation also affects the mechanisms of weakening the vascular integrity through the promotion of leukocyte adhesion, endothelial apoptosis, and widespread microthrombosis. The mechanisms were linked to clinical presentation of acute respiratory disease syndrome (ARDS), myocarditis, acute kidney disease, coagulopathy, nervous system issues (encephalopathy and cerebrovascular accident) [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. It is worth noting that the overall results of autopsy analysis revealed that microthrombi and capillary congestion were prevalent in the lungs and even in heart, kidney, liver, and brain. Therefore, a systemic involvement is beneficial in the idea that COVID-19 is an endothelial disease where microvascular damage is the universal factor in connecting infection to multi-organ dysfunction [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAmong the critical effects that observed to contribute to post-COVID-19 microvascular pathology are staggering of capillaries, endothelial regeneration loss, and microthrombi preservation [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Continuous low-grade inflammation may also lead to further vascular damage, meaning that microcirculatory functioning could be damage. The cause of such changes in the vascular system is the primary cause of the vast range of post-COVID-19 signs and symptoms such as chronic fatigue and exertional dyspnea and cognitive impairment [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e"},{"header":"2.0 Literature Review","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e2.1 Overview of Microvascular Damages\u003c/h2\u003e\u003cp\u003eThe terminology of Microvascular damage describes a structural and functional arteriolopathy of tissue rupture and exchange in terms of structural and functional changes of arterioles, capillaries and venules [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. SVD identified as a significant contributor to organ dysfunction even before COVID-19. Coronary microvascular dysfunction shown to cause ischemia and heart failure with preserved ejection fraction. Similarly, glomerular endothelial injury and capillary rarefaction underlie chronic kidney disease, while cerebral small vessel pathology forms the basis of white matter disease, lacunar strokes, and vascular cognitive impairment [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eBased on its pathophysiology, SVD attributed to endothelial mal-adaptation - loss of vasodilation through the mediation of nitric oxide, platelet and leucocyte adhesion, endothelial prothrombotic switch of chronic inflammation, oxidative stress, dyslipidemia and metabolic changes [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The consequence of alterations is increased obliteration of oxygen delivery and encourages tissue hypoxia and fibrosis, rarefaction of capillaries, augmented vascular rigidity and autoregulation failure. The initial microvascular dysfunctions most often remain nonclinical, and detected using functional imaging and testing (e.g. coronary flow reserve, retinal microvascular imaging, and state-of-the-art MRI scan of white-matter changes) [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Mechanisms of Microvascular Damage\u003c/h2\u003e\u003cp\u003eThe study of Sharma and Singh (2020) reviewed that a pathophysiological process of interdependent microvascular damage, endothelium activation/dysfunction, immune-mediated inflammation, and coagulation cascade abnormality, pericytes and structural remodeling loss [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Inflammatory mediators induce adhesion molecule (ICAM-1, VCAM-1) release by endothelial cells, stimulated leucocyte and endothelial migration reduces oxidative stress cell/avidity interaction of endothelial cells; inhibits vasodilation, promotes vasoconstriction [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. It can lead to both the apoptosis and barriers disruption in both sepsis and viral cases, which come about because of direct viral infection or exposure to the proteins of the virus. SARS-CoV-2 in vascular cells- ACE2 and blocks renin-angiotensin system, however, selectively stimulates vasoconstriction, inflammation, and thrombosis [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. Whereas, there is no conclusive evidence exists regarding endothelial tropism and that its expression reduced in endothelium in comparison to certain parenchymal cells, activation and damage to endothelium never reported not to happen in COVID-19 [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe contribution of coagulopathy, endotheliopathy results in development of procoagulant endothelial surface, tissue factor expression, platelet-activation, and complement interaction to micro- clotting that blocks capillaries and increases ischemia. The additional destruction of the microvascular networks presupposes the dysfunction of the pericytes and the capillary erosion with its resultant chronic hypo-perfusion and remodeling fibrotic [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e2.3 Symptoms of Microvascular Damage in COVID-19\u003c/h2\u003e\u003cp\u003eThe multi-organ hypoperfusion, inflammation, and microthrombosis correlations are heterogeneous constellations of acute and persistent symptoms that are microvascular injuries due to the coronavirus disease. Pulmonary microangiopathy, severe hypoxemia and non-responding ARDS also involves capillary congestion, endothelial cell inflammation, endothelial thrombus and barricades the gaseous exchange [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Research studies conducted in the long-term follow up indicate that outcome of a heart failure patient under functional examination is myocarditis-like symptoms and heart failure-cardiac symptoms exercise intolerance [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eA narrative review by Korompoki et al. (2021), the neurological phenomenon explained by small-vessel brain damage identified both in postmortem microvascular histopathology and MRI (microinfarcts, white-matter hyperintensities) is an association with both acute and post-acute COVID-19 - headache, encephalopathy, cognitive impairment (brain fog) and focal neurologic impairment [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Microvascular impairment, absence of endothelial repair/low grade inflammation, resulting in systemic functioning, systemic symptoms of progressively weak condition, post-exertional fatigue and orthostatic intolerance (dysautonomia) and exertional malaise is present [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. These abnormalities of endothelium and consequently role of vascular system in the syndromes have proven over many months of infection following clinical cohort studies and vascular functional studies [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003e2.4 Microvascular Complications and Predictors\u003c/h2\u003e\u003cp\u003eThe high susceptibility to the thrombotic complications are linked with the degeneration of the organ system and the abundance of the pathological correlate of microvascular thrombosis is also linked with the occurrence of thrombotic foci in the lungs, pulmonary microthrombi and venous thromboembolism [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Also along with poor results in microthrombi and endothelium harm are also similar outcomes that appeared across lungs and body in the case of autopsy studies [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e\u003cp\u003ePredictive disease outcomes depends on age are cardiovascular disease, diabetes mellitus, overweight, the existence of systemic inflammation and coagulopathy (high D-dimer, CRP, ferritin). The severity of the disease and death is also associated with heightened symptoms of the mobilization of the endothelium cells (vWF antigen, thrombomodulin) [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe criterion of assessment of anticoagulation approaches during the onset of the pandemic to prevent the risk of thrombosis was randomized and observational studies. The causality of coagulopathy in complications of non-critical population established, however, the causality of coagulopathy as the mediator of the bleeding risk and bleeding tendency of timely selection [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003e2.5 Risk Factors due to Microvascular Damage\u003c/h2\u003e\u003cp\u003eRisk factors of microvascular damage only revealed in the classic cardiometabolic risk, however, also increased the chances of other organs damage [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. It might result in capillary rarefaction and dysautoregulation as a sequela of development of preexisting endothelial dysfunction by chronic low-grade inflammation, oxidative stress, glycation, lipid peroxidation and hyperglycemia, lipidemia, obesity and smoking [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. These risk factors also precondition the most disagreeable results of COVID-19 and worse microvascular injuries during its infection [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAge is also a risk factor that can cause vascular stiffness, the unavailability of bioavailability of nitric oxide and inflammation elevate the microvascular decompensation threshold. SARS-CoV-2 virus could intervene to provoke angina pro avia organ dysfunction in the patient with innate stress of microvascular disease (diabetic retinopathy, glomerular endothelial damage by CKD) [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Genetic predilection, sexual problems, socioeconomic factors (access to care, burden of comorbidities) moderate risk and outcomes. Among the biomarkers used to identify COVID-19 patients with weakened endothelium with outsize microvascular damage are increased baseline vWF, factor Eight and pro-inflammatory cytokine [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. The measures like minimization of the danger in glycemic regulation, blood pressure regardless of the drugs, lipids reduction, smoking toleration are continuing to assume the leading part on the stage of the prevention of the chronic SVD and exposure to the danger of the definite injury vascular [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003e2.6 Effect of Covid-19 on other Organ Dysfunction\u003c/h2\u003e\u003cp\u003eThese are outcomes of microvascular brain destruction on imaging and inflammatory and coagulopathy, linked to post-COVID syndromes of the nervous system, which are manifested as cognitive disability, headaches and dysautonomia. The enduring microclots, incompleteness and capillary rarefaction of endothelium, have been proposed to be the eternal suffer-making processes [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Renal diseases present with a wide range of signs and symptoms, with most patients who survived acute kidney injuries recovering in the meantime, however, presenting a gradual malfunction, because of irreversible microvascular and interstitial damages. The risk of SVD may also increase when reported during the long-term, fresh or worsening cardiometabolic decrease (new or worsening diabetes, high blood pressure) at the post-COVID-19 stage [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\u003ch2\u003e2.7 Organ Dysfunction Post Covid-19\u003c/h2\u003e\u003cp\u003eIn the cohort study for epidemiology, higher risk of non-remitting organ dysfunction is predicted by severity of the acute illness, old age, comorbidities, and indicators of coagulopathy/inflammation [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. In patients with mild acute disease, long-term symptoms have reported, and it is even possible that microvascular damage and general immune maladaptation has experienced at both ends of the severity spectrum. Longitudinal research has continued to delimit directions and to determine reversible and progressive injury of microvascular mediation of organs. Functions of various organs are dysfunctional stunning microvascular damage with SARS-CoV-2. The absence of ventilation-perfusion correspondence and microangiopathy of the lungs are among the origins of severe hypoxemia and prolonged respiratory failure [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eKidney involvement is often a sign of a superimposition of acute tubular injury on the malfunctioning of the glomerular endothelium, endothelial swelling and microthrombi were found in kidney autopsy and heightened poorer outcome and augmented advance of chronic kidney illnesses in patients with acute kidney injury in hospital [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. In results, of microvascular inflammation and microthrombi, microinfarcts, hemorrhagic lesions and visualization of blood-brain barrier damage has linked with neurological conditions developing clinically as encephalopathy, stroke and cognitive impairment. Retina gives us a window into the health of the microvessels in the system and it has noticed that the retinal mirrors have changed following the covid and these are symptoms of the damage to the vascular system [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eMicrovascular congestion and ischemia related to liver and gastrointestinal symptoms and the endothelium dysfunction stimulates a prothrombotic condition, which, in turn, may result in the formation of multi-organ failure. The vascular footprint of COVID-19 is an explanatory characteristic of heterogeneous organ intrusions at acute and post-acute phases [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\u003ch2\u003e2.8 Effective Interventions used for Organ Dysfunctions\u003c/h2\u003e\u003cp\u003eTherapeutic interventions to control COVID-19 associated microvascular damage include anticoagulation, anti-inflammation, endothelial protective, and rehabilitation practices [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. Preliminary clinical studies with anticoagulation showed that therapeutic anticoagulation of heparin decreased thrombotic complications in hospitalized environment. According to Lucijanic et al. (2023), for patients in non-critical conditions emphasized that timely antithrombotic therapy is essential to balance thrombotic risk [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAnti-inflammatory foods (e.g., corticosteroids, IL-6 inhibitors) inhibit high-incidence inflammatory endothelial activation in acute COVID-19, decreasing progression to respiratory failure and presumed to be able to mitigate downstream microvascular damage. Statins and ACE inhibitors/ARBs postulated to have endothelial protective effects through pleiotropic anti-inflammatory and vasculo protective effects [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eFunctional correction resulting in microvascular impairment addressed by rehabilitative and supportive intervention (graded exercise, autonomic retraining, oxygen, cardiopulmonary rehabilitation). The possibilities of new regenerative strategies such as endothelial progenitor cell therapy and angiogenic or endothelial repair agents are under preclinical/early clinical trial as potential methods of repairing microcirculatory integrity. Vascular biomarker and retinal imaging and functional microcirculatory testing monitoring can inform personalized treatment and help phenotype patients, possibly to benefit more with vascular protective therapy intensification [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e"},{"header":"3.0 Methodology","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\u003ch2\u003e3.1 Research Design\u003c/h2\u003e\u003cp\u003eThe review employed integrative review design to determine, appraise and integrate published data on the relationship between COVID-19, microvascular injury and multi-organ dysfunction. The integrative review approach based on five steps model proposed by Whittemore and Knafl (2005) has employed (See Fig.\u0026nbsp;1): (1) problem identification, (2) literature search, (3) data evaluation, (4) data analysis, and (5) presentation. This methodology was chosen because it incorporates different study designs to obtain a panoramic view of a complex, multi-system condition following COVID-19 induced microvascular damage.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003e3.2 Search Strategy\u003c/h2\u003e\u003cp\u003eDifferent electronic databases, including PubMed, Scopus, Web of Science, EMBASE, CINAHL, PsycINFO, Cochrane Library, and Google Scholar used to gather information on published articles in peer-reviewed journals. The literature search has designed to constrain the search to articles published no earlier than 2019, and not later than 2025 to review the most recent output with regards to COVID-19. Searching done by using Medical Subject Headings (MeSH) along with the free-text key word to reach as many articles as possible. The keywords included: COVID-19, SARS-CoV-2, microvascular damage, small vessel disease, endothelial dysfunction, organ dysfunction, multiorgan failure, post-COVID syndrome, long COVID, post-acute sequelae of SARS-CoV-2 (PASC), microthrombosis, inflammation and endotheliitis. To enhance searching and avoid irrelevant results, these words were searched using Boolean operators such as AND, OR and NOT. Examples of such search terms might include COVID-19 AND microvascular damage AND organ dysfunction or SARS-CoV-2 AND endothelial dysfunction OR microthrombosis. Table\u0026nbsp;1 presented databases and keywords for study selection.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\u003ch2\u003e3.3 Search Strings\u003c/h2\u003e\u003cp\u003eSearch strings were developed to support the comprehensive and systematic literature search through the integration of a combination of keywords and Boolean operators (AND, OR, and NOT). Below, the unique combinations of keywords provided to each database, to optimize the retrieval of relevant articles and minimize irrelevant results.\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\"COVID-19 AND Microvascular Damage AND Organ Dysfunction AND Endothelial Injury\"\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\"SARS-CoV-2 AND Small Vessel Disease OR Capillary Dysfunction AND Inflammation\"\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\"Post-COVID Syndrome AND Microvascular Complications AND Multiorgan Dysfunction AND Hypoxia\"\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\"COVID-19 AND Endothelial Dysfunction AND Microthrombosis OR Organ Impairment AND Risk Factors\"\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003e3.4 Eligibility Criteria\u003c/h2\u003e\u003cp\u003eIt is important to apply eligibility criteria during the selection process to check the credibility of sources used in review article. Studies published after 2019 were included from peer-reviewed journals and written in English language considered as eligible. Selected studies included the association between COVID-19 and microvascular damage, small vessel disease, or organ dysfunction. Both review articles and clinical research studies that included human subjects were included regardless of research design. Table\u0026nbsp;2 showed the inclusion and exclusion criteria for this study.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003e3.5 Selection of Studies\u003c/h2\u003e\u003cp\u003eA preliminary search of the database located 1,280 studies. This removed 1,045 titles and abstracts. Of these, 184 articles reviewed in their entirety. Around 42 articles have selected for the final analysis and findings after applying inclusion and exclusion criteria. After final selection, some other relevant research studies that were included through a snowballing technique to determine the final 45 studies dataset.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\u003ch2\u003e3.6 Data Quality Assessment Tool\u003c/h2\u003e\u003cp\u003eTwo reviewers evaluated the selected studies independently against the methodological consistency, relevance, and microvascular pathology focus in COVID-19. Quality tools were used (CASP checklist (qualitative and observational studies) and Cochrane risk-of-bias tool (trials). The tool assists the reviewers to establish the credibility of the study findings and the evidence strength in general [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e\u003ch2\u003e3.7 Data Extraction\u003c/h2\u003e\u003cp\u003eA structured extraction form used to document data on authors, year, study design, setting, sample size, population, methodological approach, key findings, and reported microvascular / organ outcomes. Mechanisms of microvascular damage, organ specific effects, risk factors, predictors of dysfunction, and treatment methods ascertained using the thematically extracted data. Synthesized themes chosen to provide a composite perspective of the pathophysiology of microvascular injury in post-COVID organ dysfunction.\u003c/p\u003e\u003c/div\u003e"},{"header":"4.0 Results","content":"\u003cp\u003eAmong 45 selected studies for this review article, 20 sources chosen for analysis. The studies carried out in different geographical settings such as the United States, Europe, Asia, and the Middle East and their designs were narrative reviews, cross-sectional analyses, mechanistic, and clinical cohort studies.\u003c/p\u003e\u003cp\u003eMost of the studies cited for endothelial damage, microthrombosis, and microvascular inflammation to present the connection between an infection with SARS-CoV-2 and multi-organ injury. Moreover, existing research noted complications in cardiovascular, renal, pulmonary, and neurological systems in addition to persistent endothelial dysfunction in long COVID-19 [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Some investigated therapeutic approaches, including blood pressure and glucose control. Also, new targets such as microclot dissolution, mitochondrial protection and autonomic modulation. See Table\u0026nbsp;3 for the summary of selected studies with key findings. In the table 3, a summary of 20 studies provided that were included or considered for the analysis and discussion section of the review article.\u003c/p\u003e\u003cp\u003e\u003cem\u003e[Insert Table\u0026nbsp;3]\u003c/em\u003e\u003c/p\u003e"},{"header":"5.0 Discussion","content":"\u003cdiv id=\"Sec21\" class=\"Section2\"\u003e\u003ch2\u003e5.1 Microvascular Injury in Acute COVID-19\u003c/h2\u003e\u003cp\u003eThe acute infection with SARS-CoV-2 has a deep impact on the vascular system, and microvascular damage becomes one of the primary causes of dysfunction of acute organs. The endothelial cells infected through ACE2 receptors, which triggers endothelial inflammation, apoptosis, and general endothelialitis [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. This disruption of the endothelium leads to impairment of vascular homeostasis, loss of barrier integrity, increased vascular permeability, and the initiation of thrombo inflammatory cascades [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eOxidative stress, nitric oxide imbalance, and a pro-thrombotic condition are some of the unifying features of this phase [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. This leads to capillary rarefaction and poor perfusion that worsens oxygenation, particularly in tissues with high oxygen demands, like the brain, heart, and lungs [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. It also leads to the creation of a pro-inflammatory environment, which enhances the release of cytokines and the formation of microclots, which further worsen vascular pathology [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec22\" class=\"Section2\"\u003e\u003ch2\u003e5.2 Vascular Sequelae of Post COVID-19.\u003c/h2\u003e\u003cp\u003ePersistent vascular complications in survivors of COVID-19 are long-term and collectively referred to as post-COVID vascular sequelae. Such sequuelae are the result of viral persistence, immune dysregulation and unresolved endothelial damage, producing a chronic endotheliopathy state [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Attacked endothelial cells do not entirely recover their regulatory properties, causing long-lasting vascular inflammation, microclot retention, and broken repair processes [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe microvascular alterations such as fibrosis, remodeling of the extracellular matrix and rarefaction of vessels are the main targets of long-term research of vascular pathology [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. The example of vascular fibrosis in the myocardium and pulmonary circulation, which is correlated with the reduction of the vascular compliance, absence of the perfusion, and increased risk of chronic heart and lung diseases [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eCognitive impairment and fatigue are the main symptoms of post-COVID-19 which are gradually correlated with neurologically persistent microvascular dysfunction and capillary rarefaction in cerebral vessels [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. These results are accompanied by the ones indicating the existence of chronic cerebrovascular inflammation and dysfunction of neurovascular coupling as predisposing factors to the patients with vascular cognitive impairment and mood disturbances [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. The renal sequelae have been reported in which the endothelial damage of the glomerulus speeds up chronic kidney disease and irreversible renal dysfunction [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eNotably, such sequelae go beyond morphological alterations to morphological functions of the vascular regulating systems. Oxidative stress persistence, a disproportion of nitric oxide and dysfunctional mitochondriums maintain an endothelial vulnerability environment [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. This pathophysiology triggers chronic risks of hypertension, thrombosis, and cardiovascular events in the context of which there is a concern about the accelerated vascular aging of post-COVID populations [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec23\" class=\"Section2\"\u003e\u003ch2\u003e5.3 Multiple Organ Dysfunctions \u0026ndash; Evidence-Based Findings\u003c/h2\u003e\u003cp\u003eCOVID-19 has become a systemic disease whose microvasculars are extensively involved, which causes the dysfunction of many organs. There is a number of evidences that SARS-CoV-2 causes endothelial injury and capillary microthrombosis that worsen tissue perfusion and are associated with organ-specific pathologies outside the respiratory system [23). The cause of this multi-organ effect is that the viral entry occurs via angiotensin-converting enzyme 2 (ACE2) receptors that are highly expressed in the heart, kidneys, lungs, liver, and brain causing both direct viral cytotoxicity and indirect immune-mediated damage. The cardiac organ dysfunction during the Post-Covid-19 entails coronary microvascular dysfunction, and endothelial inflammation [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAnother study by Riou et al. (2024) revealed that pulmonary microvascular injury is a key cause of organ dysfunction due to endothelial cell apoptosis, fibrin deposition, and vascular remodeling that had an effect on oxygen exchange. Long-lasting pulmonary hypertension and fibrotic remodeling have been reported in post-COVID patients, which is evidence of long-term damage of alveolar capillary networks [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. This pulmonary vasculopathy is believed to be one of the major causes of long COVID chronic dyspnea and exercise intolerance. Moreover, cerebral microvascular injury such as impairment of blood brain barrier, neuroinflammation, and microthrombi are also becoming more apparent due to some dysfunction of some of the neurological organs.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec24\" class=\"Section2\"\u003e\u003ch2\u003e5.4 Therapeutic Strategies\u003c/h2\u003e\u003cp\u003eTreatment of post-COVID organ dysfunction should be based on the complex of intervention of the vascular endothelium, inflammation, and metabolism. Because endothelial damage is at the center of the COVID-19 pathology, the restoration of vascular integrity and the prevention of additional malfunction became the priorities of clinical care [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. It has been indicated in recent evidence that traditional cardiovascular, metabolic, and anti-inflammatory interventions are capable of reducing microvascular complications and enhancing long-term recovery. Blood pressure, glycemic and lipid metabolism optimization is an important factor in the minimization of endothelial stress and the enhancement of microcirculatory flow.\u003c/p\u003e\u003cdiv id=\"Sec25\" class=\"Section3\"\u003e\u003ch2\u003e5.4.1 Blood Pressure Control\u003c/h2\u003e\u003cp\u003eProper blood pressure management is essential in the maintenance of endothelial activity and minimization of microvascular injury after COVID. Research has found that uncontrolled hypertension increases the severity of vascular stiffness and oxidative stress to aggravate endothelial dysfunction in post-recovery patients [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. Protective effects have been proven by the use of ACE inhibitors and angiotensin receptor blockers (ARBs) that enhance the bioavailability of nitric oxide and endothelial homeostasis [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. Beta-blockers and calcium channel blockers can also help to eliminate postural tachycardia and autonomic imbalance that are commonly reported in long COVID [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec26\" class=\"Section3\"\u003e\u003ch2\u003e5.4.2 Diabetes Management\u003c/h2\u003e\u003cp\u003eOxidative stress of endothelium and inflammation by increased role of post-COVID hyperglycemia and insulin resistance. As can be seen, a strict glycemic control can enhance the vascular reactivity and decrease thrombotic complications [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. SGLT2 inhibitors, metformin and GLP-1 receptor agonists have been discovered to exhibit endothelial-protective effects and SGLT2 inhibitors to have lower post-COVID-19 diabetic inflammatory biomarker [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec27\" class=\"Section3\"\u003e\u003ch2\u003e5.4.3 Cholesterol Control\u003c/h2\u003e\u003cp\u003eOne of the risk factors of vascular inflammation is dyslipidemia, which is viewed as modifiable among long COVID patients. The pleiotropic anti-inflammatory and antioxidant effects of statins are highly recommended to address the injury of endothelial cells and enhance the production of nitric oxide [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Various observational studies have recommended statin therapy to have a positive effect on vascular compliance and a reduced post-COVID cardiovascular complication rate [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. In addition to statins, PCSK9 inhibitors and omega-3 fatty acids have also been suggested due to their possible advantages in reducing the vascular fibrosis and systemic inflammation [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec28\" class=\"Section3\"\u003e\u003ch2\u003e5.4.4 Management of Hypertension\u003c/h2\u003e\u003cp\u003eRAAS imbalance, endothelial stiffness, and persistent inflammation could be the causes of persistent hypertension after COVID-19 [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. RAAS modulators, nitric oxide donors, and antioxidant therapy have been shown to be promising therapeutic methods in terms of decreasing vascular resistance [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists have been used in combination with one another to reverse endothelial dysfunction and reduce inflammatory mediators. In addition, lifestyle changes including salt, aerobic, and stress reduction also improve vascular recovery [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. See Table\u0026nbsp;4 below, an evidence-based therapeutic strategies for post-COVID-19 microvascular and organ dysfunction (2020\u0026ndash;2025).\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e"},{"header":"6.0 Conclusion","content":"\u003cp\u003eIn conclusion, the review about microvascular dysfunction is central to the relationship between SARS-CoV-2 infection and multiple organ dysfunction that is observed in both the acute and post-acute phases of COVID-19. The results indicate that COVID-19 is not a pulmonary disease, however, a vascular system disease, which is characterized by endothelium injury, inflammation, and distortions in coagulations. The processes have disrupted specific organ microcirculation and caused cardiac, renal, hepatic and neurological complications. This review indicates that people with pre-existing diseases like hypertension, diabetes, and dyslipidemia are more susceptible to severe microvascular damage and chronic problems. Continuous symptoms such as fatigue, impaired cognition, and dysfunction of the cardiovascular system only underline the chronicity of post-COVID-19 microvascular damage.\u003c/p\u003e"},{"header":"7.0 Limitations and Strengths","content":"\u003cp\u003eThe review used published literature sources between 2019 and 2025. A number of studies involved were limited to small data size, which restricted the ability to generalize the results to other populations. The study designs and diagnostic criteria of post COVID-19 contributed to variability and comparability of the findings. This review is limited to synopsis between the microvascular injury mechanisms and the multi-organ dysfunction and therapeutic implications.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eDisclosure Statement\u003c/strong\u003e: The author declared that sources of information were cited appropriately in this review and no conflicts of interest or other financial funding exist that affected the content of this work.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgement\u003c/strong\u003e: None\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict\u003c/strong\u003e \u003cstrong\u003eof\u003c/strong\u003e \u003cstrong\u003eInterest\u003c/strong\u003e: The author declares no conflict of interest\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ePelle MC, Zaffina I, Luc\u0026agrave; S et al (2022) Endothelial dysfunction in COVID-19: potential mechanisms and possible therapeutic options. Life 12(10):1605\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAhamed J, Laurence J, Long (2022) COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Investig. ;132(15)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKoutsiaris AG, Karakousis K, Long COVID, Mechanisms (2025) Microvascular Effects, and Evaluation Based on Incidence. Life 15(6):887\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHalawa S, Aguib Y, Yacoub MH (2023) In search for molecular mechanisms of Post COVID-19 vascular damage. Cell Signal 1(1):85\u0026ndash;89\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYin J, Wang S, Liu Y et al (2021) Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation 28(7):e12718\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCrea F, Montone RA, Rinaldi R (2022) Pathophysiology of coronary microvascular dysfunction. Circ J 86(9):1319\u0026ndash;1328\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSharma VK, Singh TG (2020) Chronic stress and diabetes mellitus: interwoven pathologies. Curr Diabetes Rev 16(6):546\u0026ndash;556\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGupta G, Buonsenso D, Wood J et al (2025) Mechanistic Insights Into Long Covid: Viral Persistence, Immune Dysregulation, and Multi-Organ Dysfunction. Compr Physiol 15(3):e70019\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKei CY, Singh K, Dautov RF et al (2023) Coronary microvascular dysfunction: evolving understanding of pathophysiology, clinical implications, and potential therapeutics. Int J Mol Sci 24(14):11287\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGoerlich E, Chung TH, Hong GH et al (2024) Cardiovascular effects of the post-COVID-19 condition. Nat Cardiovasc Res 3(2):118\u0026ndash;129\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhan MN (2024) Post-COVID-19 Cardiac Complications: Understanding the Immune Niche Alterations in the Heart. Indian Practitioner. ;77(7)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang Y, Zhang J, Wang Z et al (2023) Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction. Heart Fail Rev 28(1):169\u0026ndash;178\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi J, Zhou Y, Ma J et al (2023) The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduct Target therapy 8(1):416\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSteegh FM, Keijbeck AA, de Hoogt PA et al (2024) Capillary rarefaction: a missing link in renal and cardiovascular disease? Angiogenesis 27(1):23\u0026ndash;35\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSideratou C-M, Papaneophytou C (2024) Persistent vascular complications in long COVID: The role of ACE2 deactivation, microclots, and uniform fibrosis. Infect Disease Rep 16(4):561\u0026ndash;571\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRudilosso S, Rodr\u0026iacute;guez-V\u0026aacute;zquez A, Urra X et al (2022) The potential impact of neuroimaging and translational research on the clinical management of lacunar stroke. Int J Mol Sci 23(3):1497\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMatsuishi Y, Mathis BJ, Shimojo N et al (2021) Severe COVID-19 infection associated with endothelial dysfunction induces multiple organ dysfunction: a review of therapeutic interventions. Biomedicines 9(3):279\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKamdar A, Sykes R, Thomson CR et al (2024) Vascular fibrosis and extracellular matrix remodelling in post-COVID 19 conditions. Infect Med 3(4):100147\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAshraf UM, Abokor AA, Edwards JM et al (2021) SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genom 53(2):51\u0026ndash;60\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGeorgieva E, Ananiev J, Yovchev Y et al (2023) COVID-19 complications: oxidative stress, inflammation, and mitochondrial and endothelial dysfunction. Int J Mol Sci 24(19):14876\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRamadori GP (2023) Organophosphorus poisoning: Acute respiratory distress syndrome (ARDS) and cardiac failure as cause of death in hospitalized patients. Int J Mol Sci 24(7):6658\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVisco V, Vitale C, Rispoli A et al (2022) Post-COVID-19 syndrome: involvement and interactions between respiratory, cardiovascular and nervous systems. J Clin Med 11(3):524\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eXu S-w, Ilyas I, Weng J-p (2023) Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin 44(4):695\u0026ndash;709\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVlaming-van Eijk LE, Tang G, Bourgonje AR et al (2025) Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies. J Pathol\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKruger A, Joffe D, Lloyd-Jones G et al (eds) (2024) Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers, Inc.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKorompoki E, Gavriatopoulou M, Hicklen RS et al (2021) Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect 83(1):1\u0026ndash;16\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePeluso MJ, Deeks SG (2024) Mechanisms of long COVID and the path toward therapeutics. Cell 187(20):5500\u0026ndash;5529\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHe St, Wu K, Cheng Z et al (2022) Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions. MedComm 3(4):e196\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMaltezou HC, Pavli A, Tsakris A (2021) Post-COVID syndrome: an insight on its pathogenesis. Vaccines 9(5):497\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGomazkov O (2023) Post-Covid Syndrome: Pathophysiology of Systemic Dysregulations. Biology Bull Reviews 13(6):590\u0026ndash;598\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWu X, Xiang M, Jing H et al (2024) Damage to endothelial barriers and its contribution to long COVID. Angiogenesis 27(1):5\u0026ndash;22\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGy\u0026ouml;ngy\u0026ouml;si M, Alcaide P, Asselbergs FW et al (2023) Long COVID and the cardiovascular system\u0026mdash;elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovascular Res 119(2):336\u0026ndash;356\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLucijanic M, Tjesic-Drinkovic I, Piskac Zivkovic N et al (2023) Incidence, risk factors and mortality associated with major bleeding events in hospitalized COVID-19 patients. Life 13(8):1699\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCimmino G, D\u0026rsquo;Elia S, Morello M et al (2025) Cardio-Pulmonary Features of Long COVID: From Molecular and Histopathological Characteristics to Clinical Implications. Int J Mol Sci 26(16):7668\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCampbell KA, Cammer A, Moisey LL et al (2024) Critically appraising and utilising qualitative health research evidence in nutrition practice. J Hum Nutr Dietetics 37(1):377\u0026ndash;387\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAllendes FJ, D\u0026iacute;az HS, Ortiz FC et al (2023) Cardiovascular and autonomic dysfunction in long-COVID syndrome and the potential role of non-invasive therapeutic strategies on cardiovascular outcomes. Front Med 9:1095249\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAmbrosino P, Calcaterra IL, Mosella M et al (2022) Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines 10(4):812\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCharfeddine S, Ibn Hadj Amor H, Jdidi J et al (2021) Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med 8:745758\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFekete M, Lehoczki A, Szappanos \u0026Aacute; et al (2025) Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. GeroScience. :1\u0026ndash;35\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBhattacharjee N, Sarkar P, Sarkar T (2023) Beyond the acute illness: exploring long COVID and its impact on multiple organ systems. Physiol Int 110(4):291\u0026ndash;310\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRiou M, Coste F, Meyer A et al (2024) Mechanisms of pulmonary vasculopathy in acute and long-term COVID-19: a review. Int J Mol Sci 25(9):4941\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKarakasis P, Nasoufidou A, Sagris M et al (2024) Vascular alterations following COVID-19 infection: A comprehensive literature review. Life 14(5):545\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBatiha GE-S, Al-Kuraishy HM, Al-Gareeb AI et al (2022) Pathophysiology of post-COVID syndromes: a new perspective. Virol J 19(1):158\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFedorowski A, Fanciulli A, Raj SR et al (2024) Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden. Nat Reviews Cardiol 21(6):379\u0026ndash;395\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBecker RC (2020) Anticipating the long-term cardiovascular effects of COVID-19. J Thromb Thrombolysis 50(3):512\u0026ndash;524\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Jinnah University for Women","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Microvascular dysfunction, Endothelial injury, Therapeutic strategies, COVID-19, Post-COVID-19, Organ dysfunction","lastPublishedDoi":"10.21203/rs.3.rs-7945283/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7945283/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eMicrovascular dysfunction has proven to be the central mechanism of acute infection with Post-COVID-19 in the context of long-term multi-organ complications. The review aimed to evaluate the mechanisms, clinical manifestations and treatment considerations of microvascular injury in post-COVID and COVID-19. The wide search of the literature was conducted in databases of PubMed, Scopus, and Web of Science and referred to the studies published in the interval between 2019 and 2025. The results indicate that SARS-CoV-2 causes endothelial dysfunction, oxidative stress, microthrombi formation, disrupted tissue perfusion, and inflammatory tissue damage in organs. The ongoing endothelial damage also leads to cardiovascular, renal, pulmonary, and neurocognitive adverse events of long COVID. There is also evidence that microvascular vulnerability is aggravated by pre-existing comorbid conditions including diabetes, hypertension and dyslipidemia. The therapeutic plans focus on the significance of endothelial protection by the means of blood pressure level and glucose, lipid regulation, and anti-inflammatory measures.\u003c/p\u003e","manuscriptTitle":"Post-COVID-19 Organ Dysfunction: Mechanisms of Microvascular Damage and Therapeutic Strategies","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-28 14:10:22","doi":"10.21203/rs.3.rs-7945283/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f4d74e07-83c7-45ff-aef4-47b9c8c9fa37","owner":[],"postedDate":"October 28th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":56857900,"name":"Critical Care \u0026 Emergency Medicine"}],"tags":[],"updatedAt":"2025-10-28T14:10:23+00:00","versionOfRecord":[],"versionCreatedAt":"2025-10-28 14:10:22","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7945283","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7945283","identity":"rs-7945283","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}